2
Clinical Trials associated with Autocrine PD1 antibody targets mesothelin chimeric antigen receptor T cells (Shanghai Cell Therapy Group)自分泌 PD1 抗体靶向间皮素嵌合抗原受体 T 细胞注射液在间皮素阳性晚期恶性实体瘤受试者中的I/II 期临床研究
[Translation] Phase I/II clinical study of autocrine PD1 antibody targeting mesothelin chimeric antigen receptor T cell injection in subjects with mesothelin-positive advanced malignant solid tumors
主要目的: Ia期:评估aPD1-MSLN-CAR T细胞用于标准治疗失败间皮素阳性的晚期间皮瘤、宫颈癌等恶性实体瘤受试者的安全性和耐受性,确定RP2D。
Ib期:评估aPD1-MSLN-CAR T细胞用于Ib期-队列1和队列2受试者的安全性。
次要目的:
Ia期:初步评价aPD1-MSLN-CAR T细胞用于治疗间皮素阳性晚期恶性实体瘤受试者的有效性,包括客观缓解率(ORR)、疾病控制率(DCR)、总生存期(OS)、无进展生存期(PFS)、缓解持续时间(DOR)。
Ib期:初步评价aPD1-MSLN-CAR T细胞用于治疗Ib期-队列1和队列2受试者的有效性,包括客观缓解率(ORR)、疾病控制率(DCR)、总生存期(OS)、无进展生存期(PFS)、缓解持续时间(DOR)。
[Translation] Main purpose: Phase Ia: To evaluate the safety and tolerability of aPD1-MSLN-CAR T cells in subjects with mesothelin-positive advanced mesothelioma, cervical cancer and other malignant solid tumors who have failed standard treatment, and to determine RP2D.
Phase Ib: Evaluate the safety of aPD1-MSLN-CAR T cells in Phase Ib - Cohort 1 and Cohort 2 subjects.
Secondary purpose:
Phase Ia: Preliminary evaluation of the effectiveness of aPD1-MSLN-CAR T cells in the treatment of subjects with mesothelin-positive advanced malignant solid tumors, including objective response rate (ORR), disease control rate (DCR), and overall survival (OS) ), progression-free survival (PFS), duration of response (DOR).
Phase Ib: Preliminary evaluation of the effectiveness of aPD1-MSLN-CAR T cells in the treatment of subjects in Phase Ib-Cohort 1 and Cohort 2, including objective response rate (ORR), disease control rate (DCR), overall survival (OS) ), progression-free survival (PFS), duration of response (DOR).
An exploratory study evaluating the efficacy of Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) combined with PD1 antibody and Apatinib mesylate in the treatment of patients with advanced bone and soft tissue sarcoma
Start Date- |
Sponsor / Collaborator- |
100 Clinical Results associated with Autocrine PD1 antibody targets mesothelin chimeric antigen receptor T cells (Shanghai Cell Therapy Group)
100 Translational Medicine associated with Autocrine PD1 antibody targets mesothelin chimeric antigen receptor T cells (Shanghai Cell Therapy Group)
100 Patents (Medical) associated with Autocrine PD1 antibody targets mesothelin chimeric antigen receptor T cells (Shanghai Cell Therapy Group)
100 Deals associated with Autocrine PD1 antibody targets mesothelin chimeric antigen receptor T cells (Shanghai Cell Therapy Group)